| Primary |
| Product Used For Unknown Indication |
40.1% |
| Glycogen Storage Disease Type Ii |
33.8% |
| Premedication |
17.5% |
| Pain |
1.2% |
| Anxiety |
0.9% |
| Depression |
0.7% |
| Migraine |
0.7% |
| Contraception |
0.5% |
| Fabry's Disease |
0.5% |
| Headache |
0.5% |
| Hypertension |
0.5% |
| Multiple Allergies |
0.5% |
| Rhinorrhoea |
0.5% |
| Constipation |
0.4% |
| Cough |
0.4% |
| Gastrooesophageal Reflux Disease |
0.4% |
| Medical Diet |
0.4% |
| Arthralgia |
0.2% |
| Back Pain |
0.2% |
| Blood Cholesterol Increased |
0.2% |
|
| Hospitalisation |
10.3% |
| Fall |
9.0% |
| Death |
7.7% |
| Pain |
6.4% |
| Pneumothorax |
6.4% |
| Femur Fracture |
5.1% |
| Infection |
5.1% |
| Myocardial Infarction |
5.1% |
| Dyspnoea |
3.8% |
| Fatigue |
3.8% |
| Neoplasm Malignant |
3.8% |
| Paraesthesia |
3.8% |
| Respiratory Failure |
3.8% |
| Serum Sickness |
3.8% |
| Skin Lesion |
3.8% |
| Small Intestinal Obstruction |
3.8% |
| Therapeutic Response Decreased |
3.8% |
| Urticaria |
3.8% |
| Weight Decreased |
3.8% |
| Abnormal Behaviour |
2.6% |
|
| Secondary |
| Premedication |
33.1% |
| Product Used For Unknown Indication |
30.6% |
| Glycogen Storage Disease Type Ii |
25.0% |
| Anxiety |
3.2% |
| Migraine |
3.2% |
| Blood Pressure |
2.4% |
| Pain |
2.4% |
|
| Local Swelling |
15.0% |
| Paraesthesia |
15.0% |
| Skin Lesion |
15.0% |
| C-reactive Protein Increased |
5.0% |
| Fall |
5.0% |
| Fatigue |
5.0% |
| Hip Fracture |
5.0% |
| Muscle Spasms |
5.0% |
| Pain |
5.0% |
| Pain In Extremity |
5.0% |
| Pneumonia |
5.0% |
| Presyncope |
5.0% |
| Sepsis |
5.0% |
| Serum Sickness |
5.0% |
|
| Concomitant |
| Weight Decreased |
33.3% |
| Anxiety |
16.7% |
| Depression |
16.7% |
| Enzyme Abnormality |
16.7% |
| Hypertension |
16.7% |
|
|
